• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Cutera® Announces Third Quarter 2024 Financial Results

    11/7/24 4:01:00 PM ET
    $CUTR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $CUTR alert in real time by email

    CUTERA, INC. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, today reported financial results for the third quarter ended September 30, 2024.

    • Consolidated revenue for the third quarter of 2024 of $32.5 million
    • Cash, cash equivalents, and restricted cash of $59.0 million
    • AviClear growth of 16% vs prior year period driven by international capital system sales
    • Global core capital growth of 7% on a sequential quarterly basis
    • Full-year guidance maintained for both revenue and year-end cash balance

    "Our third quarter reflects consistent execution against our strategic priorities, with core capital sales improving on a sequential basis, AviClear continuing to grow year-over-year driven by strong sales and utilization in international markets, and favorable underlying trends in our gross margin and operating expense profile," commented Taylor Harris, Chief Executive Officer of Cutera, Inc. "We remain focused on expanding access to AviClear, our breakthrough technology for the treatment of acne, through training and education, practice development, and clinical indication expansion."

    Third Quarter 2024 Financial Highlights

    Consolidated revenue for the third quarter of 2024 was $32.5 million, a decrease of 30% compared to the third quarter 2023. Revenue in the third quarter of 2023 included skincare revenue of $7.1 million; following the termination of our skincare distribution agreement in February 2024, the third quarter of 2024 did not include skincare revenue. Revenue related to capital systems sales declined 17%, while recurring sources of revenue, excluding skincare, declined 19%.

    Gross profit was $1.8 million, or 6% of revenue for the third quarter of 2024, compared to a gross profit of $6.5 million, or 14% of revenue, for the third quarter of 2023. On a non-GAAP basis, gross profit was $3.7 million, or 12% of revenue, for the third quarter of 2024, compared to $9.0 million, or 19%, for the third quarter of 2023. Gross profit in the third quarter, on a GAAP and a non-GAAP basis, was negatively affected by $10.1 million, or 31% of revenue, of non-cash expense related to excess and obsolete inventory.

    Operating expenses were $38.0 million for the third quarter of 2024, compared to $47.4 million in the prior year period. On a non-GAAP basis, operating expenses were $34.7 million for the third quarter of 2024, compared to $39.8 million for the prior year period. Operating expenses for the third quarter of 2024, on a GAAP and non-GAAP basis, include a $5.4 million charge related to doubtful accounts receivable. The Company no longer adjusts for costs related to a retention plan implemented in April 2023, in its Reconciliation of Non-GAAP Financial Measures. Accordingly, the Company has not adjusted for $0.4 million of retention plan costs incurred in the third quarter of 2024. Further, the Company has revised the presentation of current and prior year periods to remove adjustments related to retention plan costs of $4.0 million for the nine months ending September 30, 2024, and $1.4 million and $4.3 million, in the three and nine months ended September 30, 2023, respectively.

    GAAP operating loss was $36.2 million and $40.9 million for the third quarters of 2024 and 2023, respectively. Non-GAAP operating loss was $31.0 million for the third quarter of 2024, compared to a Non-GAAP operating loss of $30.9 million for the third quarter of 2023.

    Cash, cash equivalents, and restricted cash, were $59.0 million as of September 30, 2024, compared to $84.3 million as of June 30, 2024.

    2024 Outlook

    Management is reaffirming full-year revenue guidance of $140 million to $145 million, as well as guidance for year-end 2024 cash, cash equivalents and restricted cash of approximately $40 million.

    Conference Call

    The Company's management will host a conference call to discuss these results and related matters today at 1:30 p.m. PT (4:30 p.m. ET). Participating in the call will be Taylor Harris, Chief Executive Officer, Stuart Drummond, Interim Chief Financial Officer, and Shelby Eckerman, Vice President, Finance.

    Participants can register for the conference call at this registration link. Upon registering, a calendar booking will be provided by email including the dial-in details and a unique PIN to access the call. Using this process will by-pass the operator and avoid the call queue. Registration will remain open until the end of the live conference call.

    If participants prefer to dial in and speak with an operator, dial Canada/USA Toll Free: 1-844-763-8274 or +1-647-484-8814. It is recommended that you call in 10 minutes prior to the scheduled start time if you are using one of these operator-assisted phone numbers.

    The call will also be webcast and can be accessed from the Investor Relations section of Cutera's website at http://www.cutera.com/. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

    About Cutera, Inc.

    Cutera is a leading provider of aesthetic and dermatology solutions for practitioners worldwide. For over 25 years, Cutera has strived to improve lives through medical aesthetic technologies that are driven by science and powered through partnerships. For more information, call 1-888-4-CUTERA or visit Cutera.com.

    *Use of Non-GAAP Financial Measures

    In this press release, to supplement the Company's condensed consolidated financial statements presented in accordance with Generally Accepted Accounting Principles ("GAAP"), management has disclosed certain non-GAAP financial measures for gross profit, gross margin rate, and income or loss from operations. Non-GAAP adjustments include depreciation and amortization including contract acquisition costs, stock-based compensation, enterprise resource planning ("ERP") implementation costs, certain legal and litigation costs, costs associated with restructuring activities and the separation of its officers and other executives, gain on termination of a distribution agreement, and certain other adjustments. From time to time in the future, there may be other items that the Company may exclude if the Company believes that doing so is consistent with the goal of providing useful information to investors and management. The Company has provided a reconciliation of each non-GAAP financial measure used in this earnings release to the most directly comparable GAAP financial measure.

    The Company defines non-GAAP operating income (loss), also commonly known as adjusted EBITDA, as operating income (loss) before depreciation and amortization, stock-based compensation, ERP implementation costs, certain legal and litigation costs, severance, gain on early termination of distribution agreement, and other adjustments.

    Company management uses non-GAAP financial measures as aids in monitoring the Company's ongoing financial performance from quarter to quarter, and year to year, and for benchmarking against other similar companies. Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. These non-GAAP financial measures should be considered along with, but not as alternatives to, the operating performance measure as prescribed by GAAP. Non-GAAP financial measures for the statement of operations and net income per share exclude the following:

    Depreciation and amortization, including contract acquisition costs. The Company has excluded depreciation and amortization expense in calculating its non-GAAP operating expenses and net income measures. Depreciation and amortization are non-cash charges to current operations;

    Stock-based compensation. The Company has excluded the effect of stock-based compensation expenses in calculating its non-GAAP operating expenses and net income measures. Although stock-based compensation is a key incentive offered to the Company's employees, the Company continues to evaluate its business performance excluding stock-based compensation expenses. The Company records stock-based compensation expenses related to grants of options, employee stock purchase plans, and performance and restricted stock. Depending upon the size, timing, and terms of the grants, this expense may vary significantly but will recur in future periods. The Company believes that excluding stock-based compensation better allows for comparisons to its peer companies;

    ERP implementation costs. The Company has excluded ERP system costs related to direct and incremental costs incurred in connection with its multi-phase implementation of a new ERP solution and the related technology infrastructure costs. The Company excludes these costs because it believes that these items do not reflect future operating expenses and will be inconsistent in amounts and frequency, making it difficult to contribute to a meaningful evaluation of the Company's operating performance;

    Certain legal and litigation costs. The Company has excluded costs incurred related to its litigation against Lutronic Aesthetics as well as the settlement of $5.8 million, which is not part of the Company's ordinary course of business. The Company's complaint against Lutronic alleged misappropriation of trade secrets, violation of the Racketeer Influenced and Corrupt Organizations Act ("RICO"), interference with contractual relations and other claims. The Company excludes these costs as well as the settlement because this litigation is a result of a discrete event that was not part of the Company's business strategy, but has a significant effect on the results of operations. The costs are incidental to and do not reflect the efficiencies and effectiveness of the Company's core operations;

    Severance. The Company has excluded costs associated with restructuring activities and the separation of its officers and other executives in calculating its non-GAAP operating expenses and non-GAAP Operating Income. The Company has excluded restructuring costs because a restructuring represents a discrete event that signifies a change in the Company's strategy, but these costs are not indicative of the ongoing financial performance of the business. The Company excludes executive separation costs because executive separations are unpredictable and not part of the Company's business strategy but could have a significant impact on the results of operations;

    Gain on early termination of distribution agreement. The Company has excluded a gain recorded in connection with the early termination of a distribution agreement with ZO USA in calculating its non-GAAP operating expenses and non-GAAP operating income (loss). The Company recorded the net gain of $9.7 million in the Company's condensed consolidated statement of operations for the three months ended March 31, 2024. The Company has excluded this gain as it is not indicative of the ongoing financial performance of the business, and not part of the Company's business strategy.

    The Company believes that excluding all of the items above allows users of its financial statements to better review and assess both current and historical results of operations. The Company no longer adjusts for costs related to a retention plan implemented in April 2023, as such costs represent a normal, recurring, operating cost, and accordingly, has not adjusted for $0.4 million of retention plan costs incurred in the third quarter of 2024. Further, the Company has revised the presentation of the prior year periods to remove adjustments for retention plan costs of $1.4 million and $4.3 million, in the three and nine months ended September 30, 2023, respectively.

    Safe Harbor Statement

    Certain statements in this press release, other than purely historical information, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These statements include but are not limited to express or implied statements regarding expanding access to AviClear, and full year revenues and cash, cash equivalents and restricted cash, along with other express or implied statements regarding Cutera's plans, objectives, strategies, financial performance, guidance and outlook, product launches and performance, trends, prospects, or future events. In some cases, you can identify forward-looking statements by the use of words such as, but not limited to, "may," "could," "seek," "guidance," "predict," "potential," "likely," "believe," "will," "should," "expect," "anticipate," "estimate," "plan," "intend," "forecast," "foresee" or variations of these terms and similar expressions or the negative of these terms or similar expressions. Forward-looking statements are based on management's current expectations and beliefs and are subject to risks and uncertainties, which are difficult to predict and may cause Cutera's actual results to differ materially from the express or implied forward-looking statements herein. These forward-looking statements are not guarantees of future performance, and stockholders should not place undue reliance on forward-looking statements. There are several risks, uncertainties, and other important factors, many of which are beyond Cutera's control, that could cause its actual results to differ materially from the forward-looking statements, including risks involved with continued expansion of AviClear, Cutera's financial position and debt service requirements, and making financial projections, as well as the other risks described in the "Risk Factors" section of Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other documents filed from time to time with the United States Securities and Exchange Commission by Cutera.

    All statements made in this release are made only as of the date set forth at the beginning of this release. Accordingly, undue reliance should not be placed on forward-looking statements. Cutera undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events. If Cutera updates one or more forward-looking statements, no inference should be drawn that it will make additional updates concerning those or other forward-looking statements. Cutera's financial performance for the third quarter ended September 30, 2024, as discussed in this release, is preliminary and unaudited, and subject to adjustment.

     
    CUTERA, INC.
    CONDENSED CONSOLIDATED BALANCE SHEETS
    (in thousands)
    (unaudited)
     
     
    September 30, December 31,

    2024

    2023

    Assets
    Current assets:
    Cash and cash equivalents

    $

    57,614

     

    $

    143,612

     

    Accounts receivable, net

     

    33,150

     

     

    43,121

     

    Inventories

     

    56,908

     

     

    62,600

     

    Other current assets and prepaid expenses

     

    12,842

     

     

    19,852

     

    Total current assets

     

    160,514

     

     

    269,185

     

     
    Long-term inventories

     

    28,664

     

     

    16,283

     

    Property and equipment, net

     

    23,521

     

     

    37,275

     

    Deferred tax asset

     

    590

     

     

    579

     

    Restricted cash

     

    1,363

     

     

    -

     

    Goodwill

     

    1,339

     

     

    1,339

     

    Operating lease right-of-use assets

     

    10,593

     

     

    10,055

     

    Other long-term assets

     

    7,834

     

     

    11,575

     

    Total assets

    $

    234,418

     

    $

    346,291

     

     
    Liabilities and Stockholders' Deficit
    Current liabilities:
    Accounts payable

    $

    7,949

     

    $

    19,829

     

    Accrued liabilities

     

    35,972

     

     

    55,055

     

    Operating leases liabilities

     

    3,386

     

     

    2,441

     

    Deferred revenue

     

    8,382

     

     

    10,422

     

    Total current liabilities

     

    55,689

     

     

    87,747

     

     
    Deferred revenue, net of current portion

     

    1,689

     

     

    1,494

     

    Operating lease liabilities, net of current portion

     

    8,397

     

     

    8,887

     

    Convertible notes, net of unamortized debt issuance costs

     

    420,422

     

     

    418,695

     

    Other long-term liabilities

     

    1,095

     

     

    1,298

     

    Total liabilities

     

    487,292

     

     

    518,121

     

     
    Stockholders' deficit:
    Common stock

     

    20

     

     

    20

     

    Additional paid-in capital

     

    136,929

     

     

    131,496

     

    Accumulated deficit

     

    (389,823

    )

     

    (303,346

    )

    Total stockholders' deficit

     

    (252,874

    )

     

    (171,830

    )

    Total liabilities and stockholders' deficit

    $

    234,418

     

    $

    346,291

     

     
    CUTERA, INC.
    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
    (in thousands, except per share data)
    (unaudited)
     
    Three Months Ended Nine Months Ended
    September 30, September 30, September 30, September 30,

    2024

    2023

    2024

    2023

     
    Products $

    27,242

     

    $

    40,989

     

    $

    88,714

     

    $

    146,285

     

    Service

    5,258

     

    5,489

     

    16,956

     

    16,544

     

    Total net revenue

    32,500

     

    46,478

     

    105,670

     

    162,829

     

     
    Products

    27,991

     

    36,586

     

    75,045

     

    98,696

     

    Service

    2,696

     

    3,435

     

    8,749

     

    9,961

     

    Total cost of revenue

    30,687

     

    40,021

     

    83,794

     

    108,657

     

    Gross profit

    1,813

     

    6,457

     

    21,876

     

    54,172

     

    Gross margin %

    5.6

    %

    13.9

    %

    20.7

    %

    33.3

    %

     
    Operating expenses:
    Sales and marketing

    18,928

     

    25,808

     

    63,269

     

    88,591

     

    Research and development

    4,353

     

    4,592

     

    13,817

     

    16,844

     

    General and administrative

    14,749

     

    17,004

     

    31,951

     

    47,448

     

    Gain on early termination of distribution agreement

    -

     

    -

     

    (9,708

    )

    -

     

    Total operating expenses

    38,030

     

    47,404

     

    99,329

     

    152,883

     

    Loss from operations

    (36,217

    )

    (40,947

    )

    (77,453

    )

    (98,711

    )

    Amortization of debt issuance costs

    (580

    )

    (561

    )

    (1,726

    )

    (1,670

    )

    Interest expense on convertible notes

    (3,071

    )

    (2,939

    )

    (8,969

    )

    (8,836

    )

    Interest income

    768

     

    2,288

     

    3,248

     

    6,946

     

    Other expense (income), net

    575

     

    (1,948

    )

    (1,128

    )

    (2,564

    )

    Loss before income taxes

    (38,525

    )

    (44,107

    )

    (86,028

    )

    (104,835

    )

    Income tax expense

    493

     

    167

     

    449

     

    765

     

    Net loss $

    (39,018

    )

    $

    (44,274

    )

    $

    (86,477

    )

    $

    (105,600

    )

     
    Net loss per share:
    Basic $

    (1.94

    )

    $

    (2.22

    )

    $

    (4.31

    )

    $

    (5.32

    )

    Diluted $

    (1.94

    )

    $

    (2.22

    )

    $

    (4.31

    )

    $

    (5.32

    )

     
    Weighted-average number of shares used in per share calculations:
    Basic

    20,154

     

    19,932

     

    20,079

     

    19,858

     

    Diluted

    20,154

     

    19,932

     

    20,079

     

    19,858

     

     
    CUTERA, INC.
    CONSOLIDATED FINANCIAL HIGHLIGHTS
    (in thousands, except percentage data)
    (unaudited)
     
    Three Months Ended % Change Nine Months Ended % Change
    September 30, September 30, 2024 Vs September 30, September 30, 2024 Vs

    2024

    2023

    2023

    2024

    2023

    2023

    Revenue By Geography:
    North America $

    14,651

     

    $

    24,855

     

    -41.1

    %

    $

    49,150

     

    $

    84,494

     

    -41.8

    %

    Japan

    3,420

     

    11,529

     

    -70.3

    %

    14,847

     

    37,247

     

    -60.1

    %

    Rest of World

    14,429

     

    10,094

     

    +42.9

    %

    41,673

     

    41,088

     

    +1.4

    %

    Total Net Revenue $

    32,500

     

    $

    46,478

     

    -30.1

    %

    $

    105,670

     

    $

    162,829

     

    -35.1

    %

    International as a percentage of total revenue

    54.9

    %

    46.5

    %

    53.5

    %

    48.1

    %

    Revenue By Product Category:
    Systems
    - North America $

    9,253

     

    $

    16,982

     

    -45.5

    %

    $

    30,926

     

    $

    59,750

     

    -48.2

    %

    - Rest of World (including Japan)

    13,771

     

    10,618

     

    +29.7

    %

    40,258

     

    41,654

     

    -3.4

    %

    Total Systems

    23,024

     

    27,600

     

    -16.6

    %

    71,184

     

    101,404

     

    -29.8

    %

    Consumables

    4,218

     

    6,248

     

    -32.5

    %

    13,330

     

    20,186

     

    -34.0

    %

    Skincare

    -

     

    7,141

     

    -100.0

    %

    4,200

     

    24,695

     

    -83.0

    %

    Total Products

    27,242

     

    40,989

     

    -33.5

    %

    88,714

     

    146,285

     

    -39.4

    %

    Service

    5,258

     

    5,489

     

    -4.2

    %

    16,956

     

    16,544

     

    +2.5

    %

    Total Net Revenue $

    32,500

     

    $

    46,478

     

    -30.1

    %

    $

    105,670

     

    $

    162,829

     

    -35.1

    %

     
    CUTERA, INC.
    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
    (in thousands)
    (unaudited)
     
    Three Months Ended Nine Months Ended
    September 30, September 30, September 30, September 30,

    2024

    2023

    2024

    2023

    Cash flows from operating activities:
    Net loss

    $

    (39,018

    )

    $

    (44,274

    )

    $

    (86,477

    )

    $

    (105,600

    )

    Adjustments to reconcile net loss to net cash used in operating activities:
    Stock-based compensation

     

    1,841

     

     

    1,616

     

     

    5,543

     

     

    6,552

     

    Depreciation and amortization

     

    1,669

     

     

    1,987

     

     

    5,464

     

     

    5,225

     

    Amortization of contract acquisition costs

     

    1,113

     

     

    3,016

     

     

    3,882

     

     

    7,085

     

    Amortization of debt issuance costs

     

    581

     

     

    561

     

     

    1,727

     

     

    1,670

     

    Deferred tax assets

     

    (82

    )

     

    19

     

     

    (11

    )

     

    62

     

    Provision for credit losses

     

    4,931

     

     

    3,574

     

     

    9,739

     

     

    5,488

     

    Accretion of discount on investment securities and investment income, net

     

    -

     

     

    902

     

     

    -

     

     

    1,048

     

    Changes in assets and liabilities:
    Accounts receivable

     

    (3,402

    )

     

    276

     

     

    232

     

     

    (9,755

    )

    Inventories

     

    11,841

     

     

    2,317

     

     

    3,259

     

     

    1,781

     

    Other current assets and prepaid expenses

     

    118

     

     

    5,128

     

     

    7,010

     

     

    4,352

     

    Other long-term assets

     

    (142

    )

     

    (860

    )

     

    (472

    )

     

    (5,642

    )

    Accounts payable

     

    (9,668

    )

     

    (3,069

    )

     

    (11,880

    )

     

    (4,735

    )

    Accrued liabilities

     

    5,737

     

     

    (7,157

    )

     

    (18,704

    )

     

    (10,963

    )

    Operating leases ,net

     

    (27

    )

     

    (14

    )

     

    (83

    )

     

    (44

    )

    Deferred revenue

     

    (234

    )

     

    (899

    )

     

    (1,845

    )

     

    (390

    )

    Net cash used in operating activities

     

    (24,742

    )

     

    (36,877

    )

     

    (82,616

    )

     

    (103,866

    )

    Cash flows from investing activities:
    Acquisition of property and equipment

     

    (173

    )

     

    (5,534

    )

     

    (1,390

    )

     

    (30,642

    )

    Proceeds from disposal of property and equipment

     

    -

     

     

    -

     

     

    63

     

     

    -

     

    Proceeds from maturities of marketable investments

     

    -

     

     

    41,044

     

     

    193,903

     

    Purchases of marketable investments

     

    -

     

     

    -

     

     

    -

     

     

    (23,467

    )

    Net provided by (used in) cash used in investing activities

     

    (173

    )

     

    35,510

     

     

    (1,327

    )

     

    139,794

     

    Cash flows from financing activities:
    Proceeds from exercise of stock options and employee stock purchase plan

     

    -

     

     

    465

     

     

    -

     

     

    1,323

     

    Taxes paid related to net share settlement of equity awards

     

    (26

    )

     

    (87

    )

     

    (110

    )

     

    (3,273

    )

    Payments on finance lease obligation

     

    (393

    )

     

    (149

    )

     

    (582

    )

     

    (386

    )

    Net cash provided by (used in) financing activities

     

    (419

    )

     

    229

     

     

    (692

    )

     

    (2,336

    )

    Net increase (decrease) in cash, cash equivalents and restricted cash

     

    (25,334

    )

     

    (1,138

    )

     

    (84,635

    )

     

    33,592

     

    Cash, cash equivalents, and restricted cash at beginning of period

     

    84,311

     

     

    181,354

     

     

    143,612

     

     

    146,624

     

    Cash, cash equivalents, and restricted cash at end of period

    $

    58,977

     

    $

    180,216

     

    $

    58,977

     

    $

    180,216

     

     

    CUTERA, INC.

    Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measure

    (in thousands)

     
    Three Months Ended September 30, 2024 Gross Profit Gross Margin Operating

    Expenses
    Operating

    Income
    Reported

    $

    1,813

     

    5.6

    %

    $

    38,030

    $

    (36,217

    )

    Adjustments:
    Depreciation and amortization including contract acquisition costs

     

    1,643

     

    5.1

    %

     

    1,138

     

    2,781

     

    Stock-based compensation

     

    102

     

    0.3

    %

     

    1,739

     

    1,841

     

    Legal - Lutronic settlement

     

    -

     

    0.0

    %

     

    -

     

    -

     

    Severance

     

    189

     

    0.6

    %

     

    454

     

    643

     

    Gain on early termination of distribution agreement

     

    -

     

    0.0

    %

     

    -

     

    -

     

    Other adjustments

     

    -

     

    0.0

    %

     

    -

     

    -

     

     
    Total adjustments

     

    1,934

     

    6.0

    %

     

    3,331

     

    5,265

     

    Non-GAAP

    $

    3,747

     

    11.5

    %

    $

    34,699

    $

    (30,952

    )

     
     
    Three Months Ended September 30, 2023 Gross Profit Gross Margin Operating

    Expenses
    Operating

    Income
    Reported

    $

    6,457

     

    13.9

    %

    $

    47,404

    $

    (40,947

    )

    Adjustments:
    Depreciation and amortization including contract acquisition costs

     

    2,371

     

    5.1

    %

     

    2,361

     

    4,732

     

    Stock-based compensation

     

    (19

    )

    0.0

    %

     

    1,636

     

    1,617

     

    ERP implementation cost

     

    -

     

    0.0

    %

     

    1,456

     

    1,456

     

    Legal - Lutronic expense

     

    -

     

    0.0

    %

     

    561

     

    561

     

    Severance

     

    151

     

    0.3

    %

     

    191

     

    342

     

    Board of Directors legal and advisory fees

     

    -

     

    0.0

    %

     

    1,280

     

    1,280

     

    Other adjustments

     

    -

     

    0.0

    %

     

    97

     

    97

     

     
    Total adjustments

     

    2,503

     

    5.4

    %

     

    7,582

     

    10,085

     

    Non-GAAP

    $

    8,960

     

    19.3

    %

    $

    39,822

    $

    (30,862

    )

    Nine Months Ended September 30, 2024 Gross Profit Gross Margin Operating

    Expenses
    Operating

    Income
    Reported

    $

    21,876

    20.7

    %

    $

    99,329

     

    $

    (77,453

    )

    Adjustments:
    Depreciation and amortization including contract acquisition costs

     

    5,564

    5.3

    %

     

    3,782

     

     

    9,346

     

    Stock-based compensation

     

    395

    0.4

    %

     

    5,148

     

     

    5,543

     

    Legal - Lutronic settlement

     

    -

    0.0

    %

     

    (5,750

    )

     

    (5,750

    )

    Severance

     

    285

    0.3

    %

     

    1,257

     

     

    1,542

     

    Gain on early termination of distribution agreement

     

    -

    0.0

    %

     

    (9,708

    )

     

    (9,708

    )

    Other adjustments

     

    -

    0.0

    %

     

    263

     

     

    263

     

     
    Total adjustments

     

    6,244

    5.9

    %

     

    (5,008

    )

     

    1,236

     

    Non-GAAP

    $

    28,120

    26.6

    %

    $

    104,337

     

    $

    (76,217

    )

     
     
    Nine Months Ended September 30, 2023 Gross Profit Gross Margin Operating

    Expenses
    Operating

    Income
    Reported

    $

    54,172

    33.3

    %

    $

    152,883

     

    $

    (98,711

    )

    Adjustments:
    Depreciation and amortization including contract acquisition costs

     

    5,968

    3.7

    %

     

    6,342

     

     

    12,310

     

    Stock-based compensation

     

    706

    0.4

    %

     

    5,847

     

     

    6,553

     

    ERP implementation cost

     

    -

    0.0

    %

     

    2,744

     

     

    2,744

     

    Legal - Lutronic expense

     

    -

    0.0

    %

     

    1,607

     

     

    1,607

     

    Severance

     

    270

    0.2

    %

     

    621

     

     

    891

     

    Board of Directors legal and advisory fees

     

    -

    0.0

    %

     

    8,989

     

     

    8,989

     

    Other adjustments

     

    307

    0.2

    %

     

    682

     

     

    989

     

     
    Total adjustments

     

    7,251

    4.5

    %

     

    26,832

     

     

    34,083

     

    Non-GAAP

    $

    61,423

    37.7

    %

    $

    126,051

     

    $

    (64,628

    )

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241107740612/en/

    Get the next $CUTR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CUTR

    DatePrice TargetRatingAnalyst
    3/22/2024Underperform → Mkt Perform
    William Blair
    7/27/2023$14.00 → $18.00Underweight → Neutral
    Piper Sandler
    5/11/2023Outperform → Mkt Perform
    William Blair
    5/10/2023$14.00Underweight
    Piper Sandler
    3/30/2023Buy → Hold
    Maxim Group
    1/31/2023Mkt Perform
    William Blair
    1/11/2023$85.00 → $33.00Overweight → Neutral
    Cantor Fitzgerald
    12/28/2022$78.00 → $68.00Overweight
    Stephens
    More analyst ratings

    $CUTR
    SEC Filings

    See more
    • SEC Form EFFECT filed by Cutera Inc.

      EFFECT - CUTERA INC (0001162461) (Filer)

      3/26/25 12:15:06 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form POS AM filed by Cutera Inc.

      POS AM - CUTERA INC (0001162461) (Filer)

      3/25/25 6:30:00 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 25 filed by Cutera Inc.

      25 - CUTERA INC (0001162461) (Filer)

      3/20/25 12:48:01 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CUTR
    Financials

    Live finance-specific insights

    See more
    • Cutera® Announces Third Quarter 2024 Financial Results

      CUTERA, INC. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, today reported financial results for the third quarter ended September 30, 2024. Consolidated revenue for the third quarter of 2024 of $32.5 million Cash, cash equivalents, and restricted cash of $59.0 million AviClear growth of 16% vs prior year period driven by international capital system sales Global core capital growth of 7% on a sequential quarterly basis Full-year guidance maintained for both revenue and year-end cash balance "Our third quarter reflects consistent execution against our strategic priorities, with core capital sales improving on a sequential basis, AviClear continuing to

      11/7/24 4:01:00 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera® to Announce Third Quarter Results on November 7, 2024

      Cutera, Inc. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, announced today that it will report financial results for the third quarter ended September 30, 2024, after the market closes on Thursday, November 7, 2024. The Company's management will host a conference call to discuss these results and related matters at 1:30 p.m. PT (4:30 p.m ET) that same day. Participants can register for the conference call at the following registration link. Upon registering, a calendar booking will be provided by email including the dial-in details and a unique PIN to access the call. Using this process will by-pass the operator and avoid the call queue. Registration will remai

      10/7/24 6:48:00 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera® Announces Second Quarter 2024 Financial Results

      CUTERA, INC. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, today reported financial results for the second quarter ended June 30, 2024. Consolidated revenue for the second quarter of 2024 of $34.4 million Cash, cash equivalents, and restricted cash of $84.3 million AviClear growth of 41% vs prior year period driven by international capital system sales Service growth of 7% vs prior year period, highlighting improvements in field service and overall customer support Completion of the Q4 2023 corporate restructuring program, and announcement of additional cost reduction initiatives, allowing for both improved cost structure and better organization al

      8/8/24 4:01:00 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CUTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $CUTR
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $CUTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Chief Legal Officer Patton Stephana Eilene covered exercise/tax liability with 623 shares, decreasing direct ownership by 0.80% to 77,216 units (SEC Form 4)

      4 - CUTERA INC (0001162461) (Issuer)

      2/21/25 1:43:37 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Executive Officer Harris Taylor C. covered exercise/tax liability with 4,620 shares, decreasing direct ownership by 2% to 255,744 units (SEC Form 4)

      4 - CUTERA INC (0001162461) (Issuer)

      2/21/25 1:42:45 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 3 filed by new insider Wierbicki Paul

      3 - CUTERA INC (0001162461) (Issuer)

      2/19/25 4:04:44 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera® Successfully Completes Restructuring Transaction and Moves Forward with Enhanced Capital Structure

      Emerges from Chapter 11 as a stronger company, well positioned for long-term growth Continuing to provide best-in-class aesthetic and dermatology solutions to customers CUTERA, INC., ("Cutera" or "the Company"), a leading provider of aesthetic and dermatology solutions, today announced that the Company has successfully completed its financial restructuring process and emerged from Chapter 11. Cutera emerges with a significantly stronger balance sheet, well positioned to drive innovation and growth. Through this process, Cutera has reduced its debt by nearly $400 million, or over 90%, and raised $65 million in new money financing from its existing lenders. "Today marks a significant mile

      5/1/25 5:20:00 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera Announces Voluntarily Delisting from Nasdaq

      Cutera, Inc. ("Cutera" or the "Company") (NASDAQ:CUTR) today announced that it has formally notified The Nasdaq Stock Market LLC ("Nasdaq") of its intent to voluntarily delist its common stock from the Nasdaq Global Select Market. Cutera expects to file a Form 25 with the Securities and Exchange Commission (the "SEC") relating to the voluntary delisting of its common stock on or about March 20, 2025. The Company expects the delisting of the common stock to be effective on or about March 30, 2025. Following such delisting, the Company intends to file a Form 15 with the SEC to indefinitely suspend the Company's reporting obligations under the Securities Exchange Act of 1934, as amended. The s

      3/10/25 3:41:00 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera Takes Steps to Strengthen Financial Foundation and Position the Company for Long-Term Success

      Enters into agreement to reduce debt by nearly $400 million and raise $65 million of new money from existing lenders Implementing pre-packaged financial restructuring plan with strong support of lenders, expected to emerge expeditiously within 60 days Continues to operate as usual and provide best-in-class aesthetic and dermatology solutions to customers CUTERA, INC., ("Cutera" or "the Company"), a leading provider of aesthetic and dermatology solutions, today announced that it is initiating a restructuring transaction with the support of a group of existing lenders, representing approximately 74% of the Company's notes, to strengthen its balance sheet and position Cutera for long-term s

      3/5/25 7:10:00 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cutera Inc.

      SC 13G/A - CUTERA INC (0001162461) (Subject)

      11/12/24 2:37:12 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cutera Inc.

      SC 13G/A - CUTERA INC (0001162461) (Subject)

      11/4/24 11:30:30 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Cutera Inc.

      SC 13D/A - CUTERA INC (0001162461) (Subject)

      9/3/24 4:14:32 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CUTR
    Leadership Updates

    Live Leadership Updates

    See more
    • Cutera® Appoints Jeryl L. Hilleman to Board of Directors

      Experienced Healthcare Executive Brings Extensive Financial and Operational Expertise to Cutera Board of Directors CUTERA, INC. (NASDAQ:CUTR), a leading provider of aesthetic and dermatology solutions, announced today that Jeryl "Jeri" Hilleman will join its Board of Directors, effective July 12, 2024. Ms. Hilleman brings over 30 years of experience in the healthcare industry, with a proven track record in financial leadership, strategic planning, operational excellence, and corporate governance. Her extensive background in life sciences and medical technology, both as a public company CFO and as a corporate director, will be invaluable to Cutera as it continues to innovate, drive towar

      6/10/24 4:30:00 PM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera Appoints Stephana Patton as Chief Legal Officer

      Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, is pleased to announce the appointment of Stephana Patton, Ph.D., J.D. as Chief Legal Officer, effective November 13, 2023. Dr. Patton will report directly to Taylor Harris, Cutera's Chief Executive Officer, and will be responsible for leading the legal, compliance, intellectual property and human resources functions. Dr. Patton brings over two decades of legal experience, focused on the life sciences industry both in private practice and as in-house counsel, to Cutera. Taylor Harris, Chief Executive Officer, said, "I am thrilled to welcome Stephana to the Cutera team. Step

      11/13/23 8:30:00 AM ET
      $CUTR
      $EIGR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Cutera, Inc. Appoints Brent Hauser as President, International

      Hauser Brings Over 20 Years of Aesthetics Industry Experience in Markets Across the Globe Cutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, is pleased to announce the appointment of Brent Hauser as President, International, effective October 2, 2023. Mr. Hauser will report directly to Taylor Harris, Cutera's Chief Executive Officer, and will be responsible for commercial performance in existing international markets, expansion into new geographies, and the international launch of AviClear, the company's pioneering energy-based device for the treatment of mild to severe acne, in 2024. Mr. Hauser brings over 20 years of aest

      10/2/23 8:30:00 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CUTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cutera upgraded by William Blair

      William Blair upgraded Cutera from Underperform to Mkt Perform

      3/22/24 7:28:54 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Cutera from Underweight to Neutral and set a new price target of $18.00 from $14.00 previously

      7/27/23 11:27:23 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Cutera downgraded by William Blair

      William Blair downgraded Cutera from Outperform to Mkt Perform

      5/11/23 7:25:52 AM ET
      $CUTR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care